Stocks and Investing
Stocks and Investing
Thu, August 15, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Colin Bristow Maintained (ABOS) at Strong Buy with Decreased Target to $6 on, Aug 15th, 2024
Colin Bristow of UBS, Maintained "Acumen Pharmaceuticals, Inc." (ABOS) at Strong Buy with Decreased Target from $14 to $6 on, Aug 15th, 2024.
Colin has made no other calls on ABOS in the last 4 months.
There are 2 other peers that have a rating on ABOS. Out of the 2 peers that are also analyzing ABOS, 0 agree with Colin's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Colin
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $15 on, Wednesday, August 14th, 2024
- David Hoang of "Citigroup" Initiated at Strong Buy and Held Target at $7 on, Thursday, July 25th, 2024
Contributing Sources